Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04266886
Other study ID # 2018-0143
Secondary ID NCI-2019-0822220
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 11, 2018
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies how well self-hypnosis works in enhancing recovery after surgery in patients with gynecologic cancer. A guided relaxation method called self-hypnosis may help affect how patients feel pain and symptoms after surgery.


Description:

PRIMARY OBJECTIVE: I. To evaluate whether participation in pre-operative self-hypnosis (SH) is feasible and will improve patients' perception of post-surgical pain, after undergoing open gynecologic surgery (laparotomy) on an enhanced recovery pathway. SECONDARY OBJECTIVES: I. To evaluate whether participation in pre-operative SH is associated with changes in use of opioid medication, including time to first postoperative opioid and total dose of opioids taken (converted to morphine equivalents) and avoidance of opioids. II. To explore whether participation in pre-operative SH is associated with changes in length of stay. III. To explore whether there are differences between the two study arms in other common symptoms of women undergoing gynecologic surgery, functional recovery after surgery and quality of life (QOL). IV. To explore whether expectations regarding symptom management or hypnotic susceptibility are related to or influence the perception of symptoms after surgery. V. To measure satisfaction with the intervention (patients on arm 2). VI. To perform sub analyses to explore whether other common clinical or demographic factors are potential covariates. EXPLORATORY OBJECTIVE: I. To compare two different instruments measuring patient reported outcomes in hospital postoperative recovery. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive usual care including receipt of multi-modal analgesia and the injection of a local analgesic at the time of surgery on the enhanced recovery after surgery (ERAS) pathway. ARM II: Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 152
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Undergoing an exploratory laparotomy for suspected gynecologic cancer, which includes metastatic disease from neoplasia originating in other organs - Planned participation in the Gynecologic Enhanced Recovery Pathway - Patient must be able to read, understand, and speak English - Consents to being part of a randomized study - Patient has physical and mental capabilities to take part in study Exclusion Criteria: - Sensitivity to amide-type local anesthetics - Patients on long-acting opioid medications, or scheduled (four or more times a day for seven or more days) short-acting opioid medications within the last 30 days - Emergency surgery of any type that does not allow for proper time for protocol review by the patient - Surgery that involves known/anticipated resection of anterior abdominal wall with plastic surgery reconstruction - Patients undergoing known/anticipated anterior abdominal wall hernia repairs - Patients undergoing pelvic exenteration - Patients with known major psychiatric disease - Patients with hearing impairment such that they are unable to hear the intervention

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Best Practice
Receive usual care
Procedure:
Hypnotherapy
Receive self-hypnosis guided relaxation
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of participating in pre-operative self-hypnosis Will assess proportion of participants who listen to the complete audio file in the preoperative holding area. Up to 1 day
Primary Patients' perception of post-surgical pain Will summarize POD1 pain scores for each treatment arm using descriptive statistics. Will use a Wilcoxon rank sums test to determine if the POD1 pain scores in the self-hypnosis arm are lower than the usual care arm. Pain intensity score from 0 to 10. Post-operative day 1 (POD1)
See also
  Status Clinical Trial Phase
Recruiting NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Phase 1
Completed NCT01641068 - Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms N/A
Active, not recruiting NCT01715168 - A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer Phase 1
Suspended NCT01356329 - Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients Phase 3
Recruiting NCT06089083 - PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
Completed NCT02518308 - Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer N/A
Active, not recruiting NCT03776253 - Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer N/A
Active, not recruiting NCT05556772 - Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic N/A
Recruiting NCT06126276 - Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) Phase 2
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT01387841 - Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting Phase 2
Completed NCT04269837 - Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer N/A
Completed NCT01433302 - Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass N/A
Completed NCT02423876 - Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery Phase 3
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Completed NCT04456140 - Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study Phase 1
Terminated NCT02818530 - Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound N/A
Recruiting NCT05786456 - e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study N/A
Recruiting NCT05625360 - REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss Phase 3
Completed NCT04258631 - Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies Phase 4